Brown Advisory Securities’s Teva Pharmaceuticals TEVA Stock Holding History

Brown Advisory Securities’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-12,970	Closed	-$433K	–	386
2017 Q2	$433K	Sell	12,970 -26,451	-67%	-$819K	0.1%	205
2017 Q1	$1.26M	Buy	+39,421	New	+$1.35M	0.31%	84
2016 Q4	–	Sell	-12,651	Closed	-$581K	–	342
2016 Q3	$581K	Sell	12,651 -7	-0.1%	-$365	0.17%	144
2016 Q2	$637K	Sell	12,658 -1,134	-8%	-$60.4K	0.2%	120
2016 Q1	$738K	Buy	13,792 +322	+2%	+$18.9K	0.24%	94
2015 Q4	$883K	Buy	13,470 +1,255	+10%	+$77.6K	0.3%	85
2015 Q3	$691K	Buy	12,215 +4,592	+60%	+$298K	0.25%	95
2015 Q2	$450K	Sell	7,623 -67	-0.9%	-$4.13K	0.15%	168
2015 Q1	$480K	Buy	+7,690	New	+$447K	0.17%	146

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Securities's TEVA Position: Q3 2017 in Review

Brown Advisory Securities sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 12,970 shares — an estimated $433K sold.

Brown Advisory Securities first reported a position in TEVA in Q1 2015 and held it in 9 quarters. The position peaked at $1.26M in Q1 2017. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Brown Advisory Securities reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Brown Advisory Securities sold 12,970 Teva Pharmaceuticals shares in Q3 2017, an estimated $433K.
Brown Advisory Securities first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 9 quarters.
Brown Advisory Securities's Teva Pharmaceuticals position peaked at $1.26M in Q1 2017.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Brown Advisory Securities's 13F filing for Q3 2017, filed 3 Nov 2017.